The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

The Business Research Company's Human Respiratory Syncytial Virus Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

As winter settles over Australia, it's not just the drop in temperature we notice - there's also a sharp rise in respiratory illnesses. Most of us are ...

A substantial burden of hospitalizations for PIV-associated ARI was observed among pediatric patients in the United States.

Infection with viruses such as influenza virus and respiratory syncytial virus (RSV ... Finally some viruses, such as coxsackie B virus, human T lymphotropic virus, Epstein–Barr virus (EBV ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The World Health Organization (WHO) published its first-ever position paper on immunization products to protect infants against respiratory syncytial virus (RSV) – the leading cause of acute lower ...

on Wednesday to recommend that high-risk patients ages 50 to 59 be vaccinated for respiratory syncytial virus (RSV), and also added a new option for meningococcal vaccination. "I don't think I can ...